GlassScriptPhysician profile
Stanley A Cohen
NPI 1457437584
$7,070.62
in general payments reported to CMS, 2019-2025
24 companies · $631 in 2025
The $631 reported for 2025 was more than what 79% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $510 · 2021: $1,354 · 2022: $1,363 · 2023: $1,288 · 2024: $1,075 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,994.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,018.36 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $783.82 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $662.03 | 2019-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $554.36 | 2022-2025 | Auvelity |
| Allergan, INC. | $488.85 | 2019-2020 | |
| Corium, LLC | $374.36 | 2022-2025 | Azstarys |
| Lundbeck LLC | $353.89 | 2019-2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $282.57 | 2019-2022 | |
| Bausch Health US, LLC | $260.93 | 2019-2024 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $220.49 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.39 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $172.68 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $153.61 | 2021-2024 | |
| Livanova USA, INC. | $117.65 | 2021 | |
| Evoke Pharma, INC. | $107.53 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $89.80 | 2023-2024 | Dyanavel Xr |
| Alkermes, INC. | $45.22 | 2024 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $40.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.74 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $31.60 | 2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $29.81 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $21.48 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $17.53 | 2019 | |
| Eisai INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.